Author Archive for: Tam
About Tam
This author has not written his bio yet.
But we are proud to say that Tam contributed 43 entries already.
Entries by Tam
Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study
/in NewsThis is big news! The ability to inhibit oncogenic BRAF in PLGAs by DAY101 (formerly TAK580) was discovered right here at Dana-Farber by investigators supported by the PLGA Foundation. This therapy would not exist without the vision, determination and persistence of our team of families, donors, basic scientists, clinicians and industry. An amazing example of […]
#GearUpShowUpCare
/in News#GearUpShowUpCare Team DFCI Lab Rats is ready to #GearUpShowUpCare See everyone at the first ever virtual Geared Up for Kids event this Sunday, May 31 at 7 PM. To join us, please register here.
Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes
/in Featured, Featured PublicationsDr. Mike Eck and colleagues have published their tour de force structural study of BRAF in complex with MEK and 14-3-3 dimers. This work explains longstanding questions about the biochemical behavior of BRAF and provides a foundation for understanding BRAF activation by oncogenic mutations as well as pharmacologic inhibition. Please go to: https://www.ncbi.nlm.nih.gov/pubmed/31581174 to read […]
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.
/in Featured, Featured PublicationsIn this featured publication, lead authors Zachary Reitman, MD, PhD and Brenton Paolella, PhD, and others with Mimi Bandopadhayay, MBBS, PhD and Rameen Beroukhim, MD, PhD use single cell sequencing technology to examine the cellular state of individual tumor cells. They find that PA cancer cells often look like astrocytes at the RNA level, but […]
Management of pediatric low-grade gliomas
/in Featured, Featured PublicationsIn this featured publication, investigators review recent results of treatments for pediatric low-grade gliomas, including standard chemotherapy, therapies targeting the mitogen-activated protein kinase (MAPK) pathway, and proton-beam radiation therapy.
Dana-Farber helps “Flip the Switch” with the Pediatric Brain Tumor Foundation
/in NewsDana-Farber’s Susan Chi, MD, Jill MacDonald, RN, BSN, CPON, Mimi Bandopadhayay, PhD, MBBS, and Larisa Condurat, PhD help the Pediatric Brain Tumor Foundation “Flip the Switch” on December 27th to light up the Prudential Center in support of pediatric brain tumor research.
Geared Up for Kids 2018
/in NewsTeam Lab Rats had so much fun this year and raised some $ too! We can’t wait to bike/run/walk again next year! In the meantime, we’ll be working hard in the lab.
Brainstem angiocentric gliomas with MYB-QKI rearrangements.
/in Featured, Featured PublicationsIn this featured publication, Drs. Bandopadhyay and Ligon examine the potential for using the MYB-QKI rearrangement as a diagnostic marker in ambiguous or atypical low-grade glioma cases.
Characterizing genomic alterations in cancer by complementary functional associations
/in Featured, Featured PublicationsIn this month’s featured publication, Drs. Hahn and Beroukhim and colleagues present REVEALER, a computational tool to investigate the functional consequences of the many mutations identified in tumor samples. Distinguishing “driver” mutations that underlie oncogenic phenotypes from “passenger” mutations with no evident functional consequences is critical to the development of effective targeted therapies. This publication demonstrates the ability of […]



